期刊文献+

肝移植后丙型病毒性肝炎复发与防治的进展 被引量:1

原文传递
导出
摘要 丙型肝炎病毒(HCV)感染已成为除乙型肝炎病毒感染外终末期肝病患者进行肝移植的主要病因。肝移植后HCV感染复发后导致移植物功能丧失,使受者存活率明显降低。有研究表明,丙型病毒性肝炎相关的终末期肝病患者接受肝移植后,超过90%的受者出现丙型病毒性肝炎复发,且复发后疾病进展明显加速,部分病例将发展成肝硬化及肝癌。因此,临床上了解肝移植后丙型病毒性肝炎复发的影响因素变得尤为迫切,预防和治疗移植后丙型病毒性肝炎的复发已成为影响肝移植成功与否的关键问题。现将肝移植后丙型病毒性肝炎复发及其防治做如下综述。
出处 《中华器官移植杂志》 CAS CSCD 北大核心 2014年第2期124-127,共4页 Chinese Journal of Organ Transplantation
  • 相关文献

参考文献31

  • 1Futagawa Y, Terasaki PI, Waki K, et al. No improvement in long-term liver transplant graft survival in the last decade: an analysis of the UNOS data[J]. Am J Transplant, 2006, 6(6) : 1398-1406.
  • 2魏来.丙型肝炎临床诊断与治疗手册[M]//毛青.移植后丙型肝炎复发的抗病毒治疗.北京:科学出版,2012:135-136.
  • 3Wunschmann S, Muller HM, Stipp CS, et al. In vitro interaction between hepatitis C virus (HCV) envelope glycoprotein E2 and serum lipoproteins (LPs) results in enhanced cellular binding of both HCV E2 and LPs[J]. J Infect Dis, 2006, 194(8) : 1058-1067.
  • 4Rosen HR, Doherty DG-, Madrigal-Estebas L, et al. Pretransplantation CD56 ( + ) innate lymphocyte populations associated with severity of hepatitis C virus recurrence[J]. Liver Transpl, 2008,14(1) : 31-40.
  • 5Berenguer M, Aguilera V, Prieto M, et al. Worse recent efficacy of antiviral therapy in liver transplant recipients with recurrent hepatitis C.. impact of donor age and baseline cirrhosis[J]. Liver Transpl, 2009,15 (7) :738-746.
  • 6Marino M, Iemmolo RM, Montalti R, et al. Predictive factors of lack of response to antiviral therapy among in patients with recurrent hepatitis C after liver transplantation[J]. Transplant Proc, 2010,42(4) : 1223-1225.
  • 7Gallegos-Orozco JF, Yosephy A, Noble B, et al. Natural history of post-liver transplantation hepatitis C: A review of factors that may influence its course[J]. Liver Transpl, 2009, 15(12) : 1872-1881.
  • 8Segev DL, Sozio SM, Shin EJ, et al. Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials[J]. Liver Transpl, 2008,14(4) : 512-525.
  • 9Ciesek S, Wedemeyer H. Immunosuppression, liver injury and post-transplant HCV recurrence[J]. Viral Hepat, 2012, 19 (1):1-8.
  • 10Sgourakis G, Radtke A, Fouzas I, et al. Corticosteroid-free immunosuppression in liver transplantation., a meta-analysis and meta-regression of outcomes[J]. Transpl Int, 2009, 22 (9) : 892-905.

二级参考文献65

  • 1何红霞,洪世雯,貌盼勇,白雁平.丙肝病毒IgM抗体检测方法的初步研究[J].中国病毒学,1996,11(3):264-267. 被引量:3
  • 2Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update[J]. Hepatology, 2009,49(4): 1335-1374.
  • 3McCaughan GW, Omata M, Amarapurkar D, et al. Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection[J]. J Gastroenterol Hepatol,2007,22(5): 615-633.
  • 4Gordon SC. Treatment of viral hepatitis-2001 [J]. Ann Med, 2001,33(6):385-390.
  • 5Pawlotsky JM. Treating hepatitis C in "difficult-to-treat" patients[J]. N Engl J Med, 2004,351 (5):422-423.
  • 6Fried MW, Jensen DM, Rodriguez-Torres M, et al. Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin[J]. Hepatology,2008,48(4): 1033-1043.
  • 7Alberti A. What are the comorbidities influencing the management of patients and the response to therapy in chronic hepatitis C? [J]. Liver Int,2009,29(Suppl 1):S15-S18.
  • 8Farnik H, Mihm U ,Zeuzem S. Optimal therapy in genotype 1 patients[J]. Liver Int, 2009,29(Suppl 1):S23-S30.
  • 9Poynard T, Colombo M, Bruix J, et al. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy[J]. Gastroenterology, 2009, 136(5):1618-1628.
  • 10Jensen DM, Marcellin P, Freilich B, et al. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha 2b: a randomized trial[J]. Ann Intern Med, 2009,150(8):528-540.

共引文献22

同被引文献11

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部